CD274 and melanoma: This approach is based on observations such as the development of resistance to B-Raf inhibitors accompanied by an upregulation of PD-L1 on melanoma cells and the influx of TILs in biopsy samples taken soon after the initiation of BRAF-V600E inhibition in patients with melanoma [114].